Single step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach

Pulmonary Pharmacology and Therapeutics

Volumn 27, Issue 2, 2014, Pages 197-207

  Patil Gadhe, Arpana ^a   Pokharkar, Varsha ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Cascade impactor; Dry powder for inhalation (DPI); Factorial design; Proliposomes; Quality by design (QbD)

Indexed keywords

LIPOSOME; OCTADECYLAMINE; PHOSPHATIDYLCHOLINE; PROLIPOSOME; RIFAPENTINE; UNCLASSIFIED DRUG; AMINE; DELAYED RELEASE FORMULATION; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG RETENTION; FACTORIAL DESIGN; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHALATIONAL DRUG ADMINISTRATION; LUNG TUBERCULOSIS; MALE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SPRAY DRYING; SUSTAINED DRUG RELEASE; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG RELEASE; HALF LIFE TIME; LUNG; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES; REGRESSION ANALYSIS; SOYBEAN; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; AMINES; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG LIBERATION; FEMALE; HALF-LIFE; LIPOSOMES; LUNG; MALE; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; RATS; REGRESSION ANALYSIS; RIFAMPIN; SOYBEANS; TISSUE DISTRIBUTION;

EID: 84895925406     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.07.006     Document Type: Article

References (43)

1. Basalious E.B., El-Sebaie W., El-Gazayerly O. Application of pharmaceutical QbD for enhancement of the solubility and dissolution of a class II BCS drug using polymeric surfactants and crystallization inhibitors: development of controlled-release tablets. AAPS PharmSciTech 2011, 12:799-810.
2. Maltesen M.J., Bjerregaard S., Hovgaard L., Havelund S., Weert M. Quality by design - spray drying of insulin intended for inhalation. Eur J Pharm Biopharm 2008, 70:828-838.
3. World Health Organisation. Tuberculosis fact sheet. Available from: [accessed 2005]. http://www.whi.int/inffs/en/fact104.html.
4. Gelperina S., Kisich K., Iseman M.D., Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005, 172:1487-1490.
5. Sharma R., Saxena D., Dwivedi A.K., Misra A. Inhalable microparticles containing drug combinations to targetalveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001, 18:1405-1410.
6. Suarez S., O'Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 2001, 18:1315-1319.
7. Sethuraman V.V., Hickey A.J. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech 2002, 3:E28.
8. Misra A., Hickey A.J., Rossi C., Borchard G., Terada H., Makino K., et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb) 2010, 91:71-81.
9. Goldbach P., Brochart H., Stamm A. Spray drying of liposomes for a pulmonary administration. I. Chemical stability of phospholipids. Drug Dev Ind Pharm 1993, 19:2611-2622.
10. Goldbach P., Brochart H., Stamm A. Spray drying of liposomes for a pulmonary administration. II. Retention of encapsulated material. Drug Dev Ind Pharm 1993, 19:2623-2636.
11. Chougule M.B., Padhi B.K., Jinturkar K.A., Misra A. Development of dry powder inhalers. Recent Patents Drug Deliv Formulation 2007, 1:11-21.
12. Bermudez L.E., Wu M., Young L.S. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin. JInfect Dis 1987, 156:510-513.
13. Pandey R., Khuller G.K. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. JAntimicrob Chemother 2004, 53:635-640.
14. Pandey R., Khuller G.K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005, 85:227-234.
15. O'Hara P., Hickey A.J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000, 17:955-961.
16. Garcia-Contreras L., Sethuraman V., Kazantseva M., Hickey A.J. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres doses in the treatment of tuberculosis in the guinea pig. JAntimicrob Chemother 2006, 58:980-986.
17. Son Y., McConville J.T. Preparation of sustained release rifampicin microparticles for inhalation. JPharm Pharmacol 2012, 64:1291-1302.
18. Ahmad Z., Pandey R., Sharma S., Khuller G.K. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents 2006, 27:409-416.
19. Farr S.J., Kellaway I.W., Carman-Meaking B. Assessing the potential of aerosol-generated liposomes from pressurised pack formulations. JControl Release 1987, 5:119-127.
20. Vyas S.P., Kannan M.E., Jain S., Mishra V., Singh P. Design of liposomal aerosols forimproved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004, 269:37-49.
21. Rojanarat W., Changsan N., Tawithong E., Pinsuwan S., Chan H.K., Srichana T. Isoniazid proliposomes powders for inhalation-preparation, characterization and cell culture studies. Int J Mol Sci 2011, 12:4414-4434.
22. Rojanarat W., Nakpheng T., Thawithong E., Yanyium N., Srichana T. Levofloxacin-proliposomes: opportunities for use in lung tuberculosis. Pharmaceutics 2012, 4:385-412.
23. Changsan N., Chan H.K., Separovic F., Srichana T. Physicochemical characterization and stability of rifampicin liposome dry powder formulation for inhalation. JPharm Sci 2009, 98:628-639.
24. Chougule M., Padhi B., Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int J Nanomedicine 2007, 2:675-688.
25. Chougule M., Padhi B., Misra A. Development of spray dried liposomal dry powder of dapsone. AAPS PharmSciTech 2008, 9:47-53.
26. Shah S.P., Misra A. Liposomal amikacin dry powder inhalers: effect of fines in invitro performance. AAPS PharmSciTech 2004, 9, 5:e65.
27. Jarvis B., Lamb H.M. Rifapentine. Drugs 1998, 56:607-616.
28. Drugs at FDA.
29. Kenny M.T., Reynolds D.L., Brackman M.A., Dulworth J.K. Comparison of biological and chemical assays for the quantification of rifapentine in human plasma. Diagn Microbiol Infect Dis 1997, 27:107-111.
30. Reith K., Keung A., Toren P.C., Cheng L., Eller M.G., Weir S.J. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab Dispos 1998, 26:732-738.
31. Ramana L.N., Sethuraman S., Ranga U., Krishnan U.M. Development of a liposomal nanodelivery system for nevirapine. JBiomed Sci 2010, 17:57.
32. Joshi M., Misra A. Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. Clin Exp Pharmacol Physiol 2003, 30:153-156.
33. Zhou K., Li J., Luo J., Zheng D.S. Crystal modification of rifapentine using different solvents. Frontiers Chem Engg China 2010, 4:65-69.
34. Zhou K., Li J., Zheng D.S. Growth, characterization and crystal structure analysis of rifapentine. JMol Struct 2010, 983:27-31.
35. Kikuchi H., Yamauchi H., Hirota S. Aspray drying method for mass production of liposomes. Chem Pharm Bull 1991, 39:1522-1527.
36. Padhi B.K., Chougule M.B., Misra A. Optimization of formulation components and characterization of large respirable powders containing high therapeutic payload. Pharm Dev Technol 2006, 11(4):465-475.
37. Vemuri S., Rhodes C.T. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv 1995, 70:95-111.
38. Kikuchi H, Hirota S, Morita H, Yachi K. Method of producing liposomal products from freeze or spray dried preparations of liposomes. US 5376380; 1994.
39. Kanchan V., Panda A.K. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007, 28:5344-5357.
40. Manconi M., Sinico C., Valenti D., Loy G., Fadda A.M. Niosomes as carrier for tretinoin. I. Preparation and properties. Int J Pharm 2002, 234:237-248.
41. Padamwar M.N., Pokharkar V.B. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability. Int J Pharm 2006, 320:37-44.
42. Biradar S.V., Patil A.R., Sudarsan G.V., Pokharkar V.B. Acomparative study of approaches used to improve solubility of roxithromycin. Powder Technol 2006, 169:22-32.
43. Malcolmson R.J., Embleton J.K. Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today 1998, 1:394-398.